Zhejiang Ausun Pharmaceutical Co., Ltd. announced a private placement of no more than 28,704,764 common shares for gross proceeds of no more than CNY 500,000,000 on March 8, 2022. The transaction included participation from no more than thirty-five specific investors, including securities investment fund management companies, securities companies, trust companies, Financial companies, asset management companies, insurance institutional investors, qualified foreign institutional investors, and other legal person investors, natural persons or other qualified investors in compliance with laws and regulations. Securities investment fund management companies, securities companies, qualified foreign institutional investors, and RMB qualified foreign institutional investors who subscribe for two or more products managed by them shall be regarded as one issuer; Fund subscription.

The transaction has been approved at the ninth meeting of the third board of directors of the company, and still needs to be reviewed and approved by the company's general meeting of shareholders and reported to the China Securities Regulatory Commission for approval. The shares issued are subject to a hold period of 6 months from the date of issuance.